Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ibuprofen - PLx Pharma

Drug Profile

Ibuprofen - PLx Pharma

Alternative Names: IBU-PC; Ibuprofen-PC; Ibuprofen-phosphatidylcholine; PL 1100; Zavryl

Latest Information Update: 15 Jun 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PLx Pharma
  • Class Amines; Analgesics; Antipyretics; Antirheumatics; Nonsteroidal anti-inflammatories; Phenylpropionates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Inflammation; Pain

Most Recent Events

  • 15 Jun 2018 Chemical structure information added
  • 20 Oct 2017 Phase-II development is ongoing for Pain and Inflammation (associated with Osteoarthritis and Rheumatoid arthritis) (PLx Pharma pipeline, October 2017)
  • 31 Jul 2015 Phase II development is ongoing for Pain and inflammation in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top